Abstract
Apart from ipilimumab and the selective BRAF inhibitors vemurafenib and dabrafenib, which have shown prolonged overall survival and progression free survival, several new targeted agents are being tested in clinical Phase II studies and are moving rapidly into pivotal registration studies. Only therapeutics that have entered a clinical Phase I–III study by the beginning of 2013 are discussed in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439:358-362.
Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107-114.
Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14:249-256.
Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-703.
Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368:1365-1366.
Patnaik A, Kang SP, Tolcher AW, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors [ASCO abstract 2512]. J Clin Oncol. 2012;30(suppl).
Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jun 2. [Epub ahead of print].
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013 Jun 2. [Epub ahead of print].
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
Herbst RS, Gordon MS, Fine GD, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors [ASCO abstract 3000]. J Clin Oncol. 2013;31(suppl).
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Healthcare
About this chapter
Cite this chapter
Schadendorf, D., Kochs, C., Livingstone, E. (2013). Emerging Therapies and Combination Approaches. In: Handbook of Cutaneous Melanoma. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-98-2_6
Download citation
DOI: https://doi.org/10.1007/978-1-908517-98-2_6
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-908517-97-5
Online ISBN: 978-1-908517-98-2
eBook Packages: MedicineMedicine (R0)